Myopia: Essilor spectacles slow progression by 60%

Interim results from a clinical trial involving 167 short-sighted children has investigated the effectiveness of the Stellest lens

child
Pixabay/Bessi
Essilor highlighted interim findings into the effectiveness of its Stellest spectacle lens for myopia management at a virtual congress of the World Society of Paediatric Ophthalmology and Strabismus on 26 September.

The company shared initial findings from an ongoing three-year clinical trial involving 167 myopic children.

Results at one year reveal that children experienced, on average, a 60% reduction in myopic progression when compared to those assigned single vision lenses.

Over this time period, eye elongation was prevented in 28% of children who wore the Stellest spectacle lens while all children wearing single vision spectacle lenses experienced eye elongation.

Essilor also highlighted that all children had adapted to their Stellest lenses within a week, and were as satisfied with the quality of their vision as children wearing single vision lenses.

The study is being conducted in partnership with Wenzhou Medical University in China.

Stellest lenses incorporate highly aspherical lenslet target (HALT) technology, which consists of a constellation of aspherical lenslets spread on 11 rings.

Essilor launched the Stellest lenses at the Wenzhou Medical University Eye Hospital in July and plans to continue a further roll out to other hospitals in China.

The company confirmed that Stellest will be launched in “several other countries,” although details are not yet available of which countries.

Previously, Hong Kong researchers have reported positive results using spectacle lenses to slow down myopic progression.

The defocus incorporated multiple segments (DIMS) lenses slowed myopic progression by 60% in a two-year randomised, double-blind clinical trial involving 160 Chinese children.